AI Article Synopsis

  • HE3235 (Apoptone) is a synthetic drug designed to target prostate and breast cancer, currently in Phase IIa trials for prostate cancer treatment.
  • Preclinical studies assessed how HE3235 interacts with nuclear hormone receptors and enzymes, showing promising safety and effective metabolite profiles in various animal models.
  • Safety studies on rats and dogs highlighted a good safety margin for human use, although certain side effects like anorexia and hypokalemia could occur at higher doses.

Article Abstract

17α-ethynyl-5α-androstane-3α, 17β-diol (HE3235, Apoptone) is an orally bioavailable synthetic analogue of 3β-androstanediol, that is active in rodent models of prostate and breast cancer, and is in Phase IIa clinical trials for the treatment of early- and late-stage prostate cancer. In preparation for clinical studies, nuclear hormone receptor and P450 interactions for HE3235 and major metabolites were characterized in vitro, and pharmacokinetics and metabolite profiles were studied in rodents, dogs, and monkeys. Four-week safety studies conducted in rats and dogs indicated a substantial margin of safety for clinical use, and no evidence of electrocardiographic or neurological effects, although anorexia, thrombocytopenia, and hypokalemia were identified as potentially dose-limiting toxicities at superpharmacological exposures. Pharmacokinetics and drug metabolism have been studied in prostate cancer patients.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-010-9517-0DOI Listing

Publication Analysis

Top Keywords

prostate cancer
8
17α-alkynyl 3α
4
3α 17β-androstanediol
4
17β-androstanediol non-clinical
4
clinical
4
non-clinical clinical
4
clinical pharmacology
4
pharmacology pharmacokinetics
4
pharmacokinetics metabolism
4
metabolism 17α-ethynyl-5α-androstane-3α
4

Similar Publications

Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis.

J Natl Cancer Inst

January 2025

Translational Radiobiology Group, Division of Cancer Sciences, University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom.

Purpose: Overlapping genes are involved with rheumatoid arthritis (RA) and DNA repair pathways. Therefore, we hypothesised that patients with a high polygenic risk score (PRS) for RA will have an increased risk of radiotherapy (RT) toxicity given the involvement of DNA repair.

Methods: Primary analysis was performed on 1494 prostate cancer, 483 lung cancer and 1820 breast cancer patients assessed for development of RT toxicity in the REQUITE study.

View Article and Find Full Text PDF

Background: Male pattern baldness (MPB) is commonly associated with prostate diseases, both of which can significantly impact men's quality of life. However, the relationship and causality between them remain unclear. In this study, we investigated the causal relationship between the two.

View Article and Find Full Text PDF

Androgen deprivation therapy (ADT) is the primary treatment strategy for prostate cancer. However, despite an initially favorable response, tumors inevitably progress to castration-resistant prostate cancer (CRPC). Therefore, the exploration of new therapeutic approaches targeting CRPC has become imperative.

View Article and Find Full Text PDF

Background: Testicular germ cell tumors (TGCTs) are the most common cancers among young men in the United States. Incidence rates among non-Hispanic White (NHW) men historically have been much higher than the rates among other men. To study whether this pattern had changed, the authors examined trends in TGCT incidence for the years 1992-2021.

View Article and Find Full Text PDF

Aim: Posterior tibial nerve stimulation (PTNS) might stimulate the sacral nerves and lead to work pelvic floor muscles. We evaluated to effects of PTNS on continence results after extraperitoneal laparoscopic radical prostatectomy (eLRP) with three trocars during early post operative period.

Methods: Prospectively recorded data of eLRP with three trocars was retrospectively reviewed for continence results between January 2017 and April 2024.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!